ClinicalTrials.gg
Active, not recruitingNCT03229200Updated Oct 30, 2025

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

A Phase 4 interventional study of Ibrutinib in Lymphoma, B-Cell, Lymphoma, Non-Hodgkin and Leukemia, B-cell, sponsored by Pharmacyclics Switzerland GmbH. Active, not recruiting at 98 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Pharmacyclics Switzerland GmbH (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
297
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing ibrutinib in Lymphoma, B-Cell — none open to participants now, 4 under way, none of them phase 3. ibrutinib · Lymphoma, B-Cell.

Enrollment
2nd of 18
297 · median 51
Started
2017
with 1 other
Phase 4
Only one
of the 18
Registered
13th of 18
by date

Among the 18 studies testing ibrutinib in Lymphoma, B-Cell, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is the only one in phase 4, and was the 13th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

None of the 18 studies testing ibrutinib in Lymphoma, B-Cell is open now. The open studies under Lymphoma, B-Cell, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing ibrutinib in Lymphoma, B-Cell as a file.
02

Study summary

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Read the detailed description

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Subjects enrolled in this treatment protocol will receive oral continuous dosing with ibrutinib at the same dose and schedule they were receiving at the end of the respective parent study. Treatment may be continued as long as the subjects continue to derive benefit from treatment with ibrutinib until such time that ibrutinib becomes commercially available for the indication of the parent study.

Clinical evaluations (including safety assessments) will be performed per local standard of care for each disease that was studied in the parent protocol. At each visit, all ongoing and new onset non-serious AEs leading to dose reduction or discontinuation, serious adverse events (SAEs), adverse events of special interest (AESI), pregnancy events, other malignancies, and special reporting situations will be recorded.

03

Conditions studied

  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin
  • Leukemia, B-cell
  • Graft Vs Host Disease
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have participated in an eligible ibrutinib clinical trial, may derive clinical benefit from continued treatment or restart of treatment with ibrutinib in the opinion of the treating physician and does not have access to commercial ibrutinib within their region and/or the drug is not reasonably accessible to the patient within the respective region.
  • Ongoing continuous treatment with ibrutinib.
  • Subject must have completed all assessments in their parent protocol and want to continue treatment with ibrutinib.
  • Subject or their legally authorized representative must voluntarily sign and date an approved by an independent ethics committee (IEC)/institutional review board (IRB) to the long term treatment extension protocol and not withdrawn consent from the parent study.
  • Male and female subjects of who agree to use both a highly effective method of and a barrier method during the period of therapy and for 90 days after the last dose of drug.

Exclusion criteria

Exclusion Criteria:

  • Meeting any requirement in the parent protocol to permanently discontinue ibrutinib treatment.
  • Any condition or situation which, in the opinion of the treating physician, may interfere significantly with a subject's participation in the protocol.
  • Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this protocol or within 90 days of last dose of drug treatment. Male subjects who plan to father a child while enrolled in this protocol or within 90 days after the last dose of drug treatment.
  • Unwilling or unable to participate in all required evaluations and procedures.
  • Unable to understand the purpose and risks of the protocol and to provide a signed and dated form (ICF) and authorization to use protected health information.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
297 participants (actual)

Study arms

  • Experimental
    Ibrutinib

    Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.

    Drug: Ibrutinib

Interventions

  • Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.

06

What researchers measure

Primary outcomes

  1. Characterize the drug safety profile by collecting long-term safety data for ibrutinib.

    Number of participants with treatment emergent serious adverse events and adverse events of special interest as assessed by CTCAE v4.0.

    Time frame: Up to 3 years and will be re-evaluated on an ongoing basis.

07

Study locations

98 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2017 (actual). Primary completion is estimated for May 2027, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jul 25, 2017
StartActual
May 22, 2017
Primary completionEst.
May 10, 2027
CompletionEst.
May 10, 2027
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03229200
Collaborators
Janssen Biotech, Inc., including Johnson & Johnson
Responsible party
Sponsor
First posted
Jul 25, 2017
Start date
May 22, 2017
Primary completion
May 10, 2027 (estimated)
Completion
May 10, 2027 (estimated)
Last update
Oct 30, 2025

Study contacts

Kevin Wu
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion